GlassScriptPhysician profile
Lourdes Labrada
NPI 1215166269
$5,910.12
in general payments reported to CMS, 2019-2025
28 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $1,401 · 2023: $944 · 2024: $1,198 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,643.89 | 2021-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $460.44 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Cleerly, INC. | $420.00 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Medtronic, INC. | $387.22 | 2023-2025 | Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Actelion Pharmaceuticals US, INC. | $319.29 | 2022-2025 | Uptravi, Opsumit |
| Abbott Laboratories | $296.08 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Aveir |
| Kestra Medical Technology Services, INC. | $239.18 | 2023-2025 | Assure Wcd |
| Novo Nordisk INC | $208.99 | 2022-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $194.09 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $164.51 | 2021-2024 | Repatha |
| Bridgebio Pharma, INC. | $155.45 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $152.90 | 2022-2023 | Optimizer |
| Pfizer INC. | $144.52 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.96 | 2021-2025 | Lifevest |
| Atricure, INC. | $139.14 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $129.09 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $117.15 | 2023-2024 | Onpattro |
| Novartis Pharmaceuticals Corporation | $115.67 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $99.34 | 2023-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $92.93 | 2021-2024 | Xarelto |
| Cvrx, INC. | $76.71 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $59.63 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $41.76 | 2023-2024 | |
| United Therapeutics Corporation | $29.18 | 2024 | Remodulin |
| Chiesi USA, INC. | $23.66 | 2025 | Kengreal, Cleviprex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.59 | 2023 | Jardiance |
| Daiichi Sankyo INC. | $19.78 | 2022 | |
| Amarin Pharma, INC. | $16.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lourdes Labrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.